Inmed's inm-901 demonstrates favorable pharmacological and behavioral effects in in vivo preclinical alzheimer's disease studies

Inm-901 receptor binding studies indicate preferential signaling agonism for cb1/cb2 and impacts the ppar signaling pathway in vivo studies demonstrate inm-901 reduces neuroinflammation and improves neuronal function molecular analysis data further explains previously reported observations in behavioral studies on locomotion, memory and cognition vancouver, british columbia--(newsfile corp. - april 4, 2024) - inmed pharmaceuticals inc. (nasdaq: inm) ("inmed" or the "company"), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, today announced additional preclinical data demonstrating inm-901's positive pharmacological effects in the potential treatment of alzheimer's disease ("ad"). dr. eric hsu, senior vice president of preclinical research and development at inmed, stated, "the recent results demonstrating pharmacological effects in in vivo disease models continue to validate inm-901 as a potential treatment of ad.
INM Ratings Summary
INM Quant Ranking